Abstract 5397
Background
Neoantigens are derived from tumor specific mutations and presented by MHC on cancer cells. The set of neoantigens likely bypass immune tolerance and less likely induce autoimmunity because they are absent from normal cells. Targeting multiple neoantigens may significantly enhance the clinical efficacy of anti-tumor treatment with less toxicity. We present the proof-of-concept clinical application of personalized neoantigens induced T cell therapy.
Methods
This open-label phase Ia clinical trial is designed to test the safety and objective response of the tumor specific antigen-induced cytotoxic T lymphocytes (TSA-CTL). This study will enroll 9 advanced melanoma patients. Participants should have measurable metastases with at least one lesion that is resectable or tumor biopsies for DNA and RNA extraction. For each patient, we generate autologous TSA-CTLs based on neoantigens which identified through machine learning approaches with exome sequencing. Patients will receive 6 doses of TSA-CTL infusion. Toxicity (endpoint 1) will be defined by Common Terminology Criteria for Adverse Events v5.0, and objective response (endpoint 2) will be determined by the Response Evaluation Criteria in Solid Tumors.
Results
Seven patients have been enrolled so far and three of them have completed 3 cycles of TSA-CTL infusion. The fifth patient display pruritus grade 1. No other related adverse events just after the treatment were observed. We detected neoantigen-specific CD8+ T cells in peripheral blood through pMHC tetramer and found that neoantigen-specific CD8+ T cell increased after the TSA-CTL infusions for the third patient and the fifth patient. After three cycles of TSA-CTL infusion, the third and the fourth patient was assessed as SD with three metastasis’ regression and PR, respectively. Further treatment and analyses are ongoing.
Conclusions
No major direct side effects are observed. Although with very limited trial subjects, a few patients did show favorable responses. Our study highlights the promise of personalized cell therapy for tumor-specific T cells and provide guidance for the future development. Clinical trial information: NCT02959905.
Clinical trial identification
NCT02959905; Release date: November 9, 2016.
Legal entity responsible for the study
BGI-Shenzhen.
Funding
BGI-Shenzhen.
Editorial Acknowledgement
Disclosure
B. Li, S. Qiu: Employee: BGI Tech Solutions (Hong Kong Co. Ltd)
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract